Business of Biotech Shorts

  1. Platforming And The Future Of Standardized Manufacturing Chassis 4/20/2026

    Platforming downstream processes offers efficiency gains, while upstream processes are standardizing on high-intensity perfusion or fed-batch. Robust analytical data allows for modern efficiencies like single-use systems.

  2. Protecting Biopharma Manufacturing Supply Chains 2/5/2026

    In this final segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” panelists Adam Golin, Jon Lindbloom, and James Sapirstein share their advice and best practices for sourcing suppliers and staying agile during periods of change in the industry.

  3. Building Resilience In Biomanufacturing Operations 2/5/2026

    In this segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” panelists share their thoughts on what it means to be resilient and how organizations can embody resilience in their biomanufacturing, which in part requires agility and preparation for the worst-case scenario. The panel was in agreement that earlier-phase companies have the highest opportunity to bake resilience into their operations.

  4. How Will U.S. Tariffs And The BIOSECURE Act Impact Global Biopharma Markets? 2/5/2026

    In this segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” panelists explain how tariffs imposed by the U.S. are putting competitive pressure on companies to reduce COGs. They also discuss the short- to long-term impact of efforts to onshore biomanufacturing.

  5. Bioprocessing Raw Material And Equipment Costs Are Slow To Recover Post-Pandemic 2/5/2026

    In this segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” our panel discusses how the still-high cost of materials and equipment is being factored into manufacturing decisions, as well as how the COVID-19 pandemic changed the way operators think about supply chains.

  6. How Is U.S. Policy Reshaping Global Biomanufacturing Operations? 2/5/2026

    In this opening segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” panelists Adam Golin, Jon Lindbloom, and James Sapirstein speak candidly about how U.S. tariffs are affecting the global operating environment.

  7. Ep. 263, Chapter 5: NIH Support and South Rampart Pharma's Path Forward With Hernan Bazan, M.D. 9/2/2025

    Despite challenges like funding fluctuations, Dr. Bazan is confident in the NIH's pivotal role in supporting biotech innovation. He believes the NIH's staff and leadership are committed to making the system more efficient, and that companies must adapt to changes in funding and grant reviews.

  8. Ep. 263, Chapter 4: South Rampart Pharma's Evolution With Hernan Bazan, M.D. 9/2/2025

    Dr. Bazan states that, nearly a decade after its 2016 founding, South Rampart Pharma is where its founders envisioned: a clinical-stage company with robust human data for its lead drug candidate, SRP-001. The company successfully completed its Phase 1 trial, demonstrating that the drug is safe and well-tolerated while also establishing favorable pharmacokinetics. With an optimized protocol, the company is now prepared for a Phase 2 trial and aims to be ready for Phase 3 within 12 months.

  9. Ep. 263, Chapter 3: The Economics of Pain Management With Hernan Bazan, M.D. 9/2/2025

    South Rampart Pharma operates with a lean business model, prioritizing R&D over large, costly operations. The company is raising an $8 million Series A to efficiently advance its lead drug candidate, SRP-001. The lean model also includes a team of fractional employees and consultants rather than full-time salaried staff. Additionally, the company focuses on a single pipeline, acute nociceptive pain, enabling them to execute a more efficient and less-dilutive Phase 2 trial. These strategies drive operational flexibility and ensure all resources are directed toward moving the technology forward.

  10. Ep. 263, Chapter 2: Better Defining And Treating Pain With Hernan Bazan, M.D. 9/2/2025

    South Rampart Pharma’s lead candidate, SRP-001, is a novel, non-opioid pain treatment whose design was inspired by the well-known liver toxicity of acetaminophen (Tylenol), which is caused by a metabolite called NAPQI. South Rampart Pharma’s medicinal chemists created a library of compounds that maintain the analgesic effects of acetaminophen while blocking the formation of this toxic metabolite. The design also aims to avoid the gastrointestinal and renal toxicities associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and the addiction risks of opioids.